📅 PUBMED DAILY TRIAGE — 2026-06-09
Window: 2026-06-08T09:00:00Z → 2026-06-09T09:00:00Z (CRDT) Topics scanned: 10 | Articles reviewed: ~100 | Candidates evaluated: 15 kept (of ~90 reviewed) High priority: 1 | Standard: 12 | Low/archive: 2 | Unsolicited finds: 0 Run status: SUCCESS
🔴🟠 HIGH PRIORITY (8+) — Best Finds by Topic
Early Cancer Detection (liquid biopsy, ctDNA, cfDNA)
TR-2026-06-09-001 / PMID 42260101 · Post-adjuvant chemotherapy in ctDNA-positive patients with resected colorectal cancer: a randomized phase 3 trial · 8/10 · The ALTAIR phase 3 RCT (n=243, Nat Med) definitively tests ctDNA-guided post-adjuvant treatment in CRC, finding FTD/TPI does NOT significantly improve DFS (HR=0.79, p=0.107) — a high-quality negative RCT that constrains the ctDNA-to-early-intervention paradigm.
Hematologic Malignancies
No high-priority (8+) articles today. Best candidate scored 7/10 (see STANDARD section).
CBC-Based Diagnostics and ML
No results — fifth consecutive sparse day. (Best standard crossover: TR-2026-06-09-010, SII in mycosis fungoides, 5/10)
AI/ML in Clinical Diagnostics
No high-priority articles today. Best candidate scored 7/10 (see STANDARD section).
Precision Oncology and Genomic Medicine
No high-priority articles today. Best candidate scored 6/10.
Novel Therapeutics (Immunotherapy, CAR-T, Targeted Therapy)
No high-priority articles today. Best candidate scored 7/10 (see STANDARD section).
Cardiovascular-Metabolic (GLP-1, SGLT2)
No high-priority articles today. Weak signal day — best candidate scored 5/10.
Aging, Longevity, and Population Health
No high-priority articles today. Best candidate scored 3/10. (See Run Notes.)
Rare Diseases with High Unmet Need
No high-priority articles today. Best candidate scored 6/10.
🟢⚪ STANDARD (5–7) — Top by Topic
Hematologic Malignancies
- TR-2026-06-09-004 / PMID 42259789 · Single-cell WGS reveals convergent evolution in Burkitt lymphoma · 7/10 · Genomics/Precision Medicine
- TR-2026-06-09-010 / PMID 42259538 · Systemic Immune-Inflammation Index as a prognostic marker in mycosis fungoides (n=126) · 5/10 · Diagnostics (CBC-derived, near-term implementable)
Early Cancer Detection / ctDNA
- TR-2026-06-09-006 / PMID 42259989 · Predictive value of serum biomarkers for survival in melanoma: systematic review and meta-analysis · 6/10 · Diagnostics (ctDNA HR=2.61 for OS)
- TR-2026-06-09-008 / PMID 42259999 · LAM-CATNet transformer-hybrid DL for mammogram classification (AUC 0.982) · 6/10 · Early Detection / Diagnostics
AI/ML in Clinical Diagnostics
- TR-2026-06-09-003 / PMID 42260279 · Federated orthogonal learning (FedOG) for liver lesion CT detection — n=3,668, 5 institutions · 7/10 · Diagnostics (federated, privacy-preserving, multi-institutional)
- TR-2026-06-09-007 / PMID 42260099 · DL spatiotemporal assessment of breast cancer lung metastases, multicenter (4 centers) · 6/10 · Diagnostics
- TR-2026-06-09-009 / PMID 42260290 · Graph theory + virtual brain modeling for prodromic dementia stratification (R²~70% with neuropsych scores) · 6/10 · Diagnostics / Early Detection
Precision Oncology / Genomic Medicine
- (PMID 42259789 listed under Hematologic Malignancies above)
Novel Therapeutics
- TR-2026-06-09-002 / PMID 42260304 · Toripalimab + cetuximab in R/M HNSCC phase 1b/2 (ORR 60% platinum-refractory, n=88) · 7/10 · Treatment Innovation
- TR-2026-06-09-011 / PMID 42260211 · CAR-T cellular therapies in SLE — review of clinical progress and future directions · 5/10 · Treatment Innovation
Cardiovascular-Metabolic
- TR-2026-06-09-012 / PMID 42260226 · Multiple metabolic indices + circadian syndrome cross-sectional study (CHARLS, n=6507) · 5/10 · Prevention / Public Health
Rare Diseases
- TR-2026-06-09-005 / PMID 42260056 · Budget impact of SMA disease-modifying therapies (nusinersen, onasemnogene, risdiplam) — US payer perspective · 6/10 · Drug Development / Public Health
- TR-2026-06-09-013 / PMID 42260322 · Co-occurring conditions and social determinants of health in Down syndrome (n=542) · 5/10 · Public Health / Prevention
💡 UNSOLICITED FINDS
No unsolicited finds today. All sentinel scan candidates either matched existing watchlist topics or scored below threshold.
📊 TODAY'S BREAKDOWN
By research category:
- Diagnostics: 6
- Early Detection: 2 (crossovers counted once)
- Treatment Innovation: 3
- Drug Development: 2
- Prevention / Public Health: 3
- Genomics/Precision Medicine: 1
By evidence maturity:
- Exploratory: 11
- Validated: 3 (PMID 42260101 phase 3 RCT, PMID 42259989 meta-analysis, PMID 42260056 BIA)
- Potentially Practice-Changing: 0
By watchlist topic (reviewed → kept → highest score):
| Topic | Reviewed | Kept | Highest Score |
|---|---|---|---|
| Hematologic malignancies | 10 | 2 | 7 |
| CBC/ML diagnostics | 0 | 0 | — |
| Early cancer detection / ctDNA | 10 | 3 | 8 ✅ |
| AI/ML diagnostics | 10 | 3 | 7 |
| Precision oncology | 10 | 2 | 6 |
| Novel therapeutics | 10 | 2 | 7 |
| Cardiovascular-metabolic | 10 | 1 | 5 |
| Aging / longevity | 10 | 0 | 3 |
| Rare diseases | 10 | 2 | 6 |
| Sentinel scan | 10 | 0 | 5 |
By source type: peer_reviewed: 15 | preprint: 0
Topics with zero 8+ articles this run: Hematologic malignancies, CBC/ML diagnostics, AI/ML diagnostics, Precision oncology, Novel therapeutics, Cardiovascular-metabolic, Aging/longevity (zero high-priority — sixth consecutive day), Rare diseases
🔧 RUN NOTES
Window expansion: Not triggered — 15 relevant records found across topics (above the 5-record threshold).
T2 (CBC/ML diagnostics): Zero results for fifth consecutive day. Recommend next run: broaden query to include "peripheral blood smear" OR "morphology" OR "flow cytometry" OR "white blood cell differential".
T8 (Aging/longevity) query update: Today's run switched from humans[MeSH] to (clinical OR cohort OR patient OR longitudinal OR trial) scoping, per prior run recommendation. Volume improved dramatically (0 → 184 results), but top-10 articles remained low-relevance to watchlist (presbylarynx, circadian syndrome crossover, exercise review). Further query refinement recommended: consider "biological aging" OR "epigenetic clock" OR "senolytic" OR "healthspan" OR "frailty index" OR "longevity intervention" as core terms.
Cardiometabolic signal: Weaker than prior week (June 5-8 were strong GLP-1/SGLT2 RCT days). Today's GLP-1-adjacent find was a drug development PROTAC paper (4/10) and a cross-sectional metabolic index study (5/10). No dedicated semaglutide/tirzepatide/SGLT2 RCTs indexed today.
Data quality: All 15 articles have PMID + abstract confirmed. No preprints indexed in this window. One title-only article (PMID 42260185, Nat Rev Clin Oncol commentary) scored LOW and not pipeline-ready.
Rolling 7-day topics with zero HIGH articles: Aging/longevity (7+ days), CBC/ML diagnostics (7+ days). Cardiometabolic topic had two 9/10 articles on 2026-06-08 (GLP-1 cancer prevention, Survodutide) but zero today — normal daily variation.
Notable: ALTAIR trial (PMID 42260101) is the second ctDNA-guided RCT from CIRCULATE-Japan to publish in recent weeks; this negative result is complementary to prior positive signals and will shape the ctDNA-guided adjuvant therapy field for CRC. HIGH alert sent.